Online monitoring of patient self-reported adverse events in early phase clinical trials: Views from patients, clinicians, and trial staff

BACKGROUND/AIMS: New classes of cancer drugs bring a range of unknown and undesirable adverse events. Adverse event monitoring is essential in phase I trials to assess toxicity and safety. In phase II, the focus is also on efficacy but robust data on adverse events continue to inform the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, Fiona, Shearsmith, Leanne, Ayres, Michael, Lindner, Oana C, Marston, Lewis, Pass, Alison, Danson, Sarah, Velikova, Galina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010887/
https://www.ncbi.nlm.nih.gov/pubmed/33231103
http://dx.doi.org/10.1177/1740774520972125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010887/
https://www.ncbi.nlm.nih.gov/pubmed/33231103
http://dx.doi.org/10.1177/1740774520972125

Ejemplares similares